The U.S. Food and Drug Administration granted emergency use authorization to Yale School of Public Health’s saliva test to detect Covid-19, after a trial on National Basketball Association players and staff.

Veracyte Inc. and Yale University announced an exclusive licensing agreement to advance the first genomic test for predicting disease progression in patients with idiopathic pulmonary fibrosis (IPF).

With a busy week for biotech quarterly and annual reports, here is a look at some of the top stories.

The U.S. Food and Drug Administration reported 1,171 generic drug approvals (935 full approvals and 236 tentative approvals) for fiscal year 2019, up from the previous all-time record total of 971 during 2018.

Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.

Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.

Yale University scientists succeeded in restoring basic cellular activity in pigs’ brains hours after their deaths in a finding that may one day lead to advances in treating human stroke and brain injuries, researchers reported.